Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Neoplasms × ACE-011 × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Classical hematology 1

Conditions

Anemia 3 Uterine Cervical Neoplasms 1 Urinary Bladder Neoplasms 1 Small Cell Lung Carcinoma 1 Neoplasms 1 Neoplasm Metastasis 1 Myelodysplastic Syndromes 1 Multiple Myeloma 1 Leukemia, Myelomonocytic, Chronic 1 Head and Neck Neoplasms 1 Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 115 Paclitaxel 92 Gemcitabine 89 Carboplatin 76 Nivolumab 57 Bevacizumab 57 Docetaxel 56 Cisplatin 48 Pemetrexed 45 Fluorouracil 42 Cyclophosphamide 39 Cetuximab 34 Capecitabine 33 Leucovorin 32 Irinotecan 32 venetoclax 31 Sorafenib 31 trametinib 29 atezolizumab 28 Erlotinib Hydrochloride 28 Dexamethasone 27 130-nm albumin-bound paclitaxel 26 Drug Therapy 25 Ipilimumab 24 Epoetin Alfa 24 Doxorubicin 23 Oxaliplatin 21 Rituximab 20 Prednisone 20 Lapatinib 20

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00931606 2023-09-13

MK-7962-012

Merck Sharp & Dohme LLC

Phase 2 Terminated

30 enrolled 32 charts

Classical hematology

Anemia, Neoplasm Metastasis, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡